Matritech regulatory update

The FDA's Immunology Devices Panel of the Medical Devices Advisory Committee will review the company's NMP22 Test Kit for bladder cancer on Nov. 30. According to the Cambridge, Mass., company,.the product is the first nuclear matrix protein-based immunodiagnostic to be reviewed by the FDA. ...